FBRX Forte Biosciences
- 0.583
- -0.011-1.77%
Forte Biosciences News
Forte Biosciences Initiated at Buy by Brookline Capital
Forte Biosciences Initiated at Buy by Brookline Capital
Brookline Capital Initiates Coverage On Forte Biosciences With Buy Rating, Announces Price Target of $4
Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $4.
Companies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite Risky
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. () (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
Forte Biosciences Q1 2024 GAAP EPS $(0.32) Misses $(0.17) Estimate
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.17) by 88.24 percent.
Forte Biosciences | 10-Q: Quarterly report
Press Release: Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update DALLAS--(BUSINESS WIRE)--May 13, 2024-- Forte Biosciences, Inc. () (NASDAQ: FBRX), a clinical-stage biopharm
Forte Biosciences 1Q Loss $7.42M >FBRX
Forte Biosciences 1Q Loss $7.42M >FBRX
Forte Biosciences Price Target Announced at $2.75/Share by Ladenburg Thalmann
Forte Biosciences Price Target Announced at $2.75/Share by Ladenburg Thalmann
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Ladenburg Thalmann: Upgraded Forte Biosciences (FBRX.US) rating from neutral to buy, with a target price of $2.75.
Ladenburg Thalmann: Upgraded Forte Biosciences (FBRX.US) rating from neutral to buy, with a target price of $2.75.
Ladenburg Thalmann Upgrades Forte Biosciences to Buy, Announces $2.75 Price Target
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences from Neutral to Buy and announces $2.75 price target.
Forte Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 292.3% Ladenburg Thalmann → $2.75 Upgrades Neutral → Buy 09/20/2021 399.29% Chardan Capital $4
Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position
Forte Biosciences GAAP EPS of -$1.00
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million
Press Release: Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update DALLAS--(BUSINESS WIRE)--March 18, 2024-- Forte Biosciences, Inc. () (NASDAQ: FBRX), a clinical-stage biopharmaceutical co
Funicular Funds, In Amended 13D Filing, Said On Oct 28, 2023, Forte Biosciences Filed Vexatious Legal Action Against Jacob Ma-Weaver And Funicular Funds; Believe Allegations In The Complaint Are Baseless And Without Merit
Funicular Funds has a 5.59% stake in Forte Biosciences
Forte Biosciences(FBRX.US) Officer Buys US$7,525 in Common Stocks
$Forte Biosciences(FBRX.US)$ Officer Wagner Paul A. purchased 10,000 shares of Common Stocks on Dec 18, 2023 at an average price of $0.7525 for a total value of $7,525.Source: Announcement What is sta
Forte Biosciences(FBRX.US) Officer Buys US$14,551.38 in Common Stocks
$Forte Biosciences(FBRX.US)$ Officer Wagner Paul A. purchased 20,520 shares of Common Stocks on Dec 13, 14, 2023 at an average price of $0.7091 for a total value of $14,551.38.Source: Announcement Wha
Analysis
Price Target
No Data
